The Medicines Company introduces new Cleviprex formulation

The Medicines Company has launched a new twelve hour formulation for the FDA approved Cleviprex Injectable Emulsion.Cleviprex is an intravenous dihydropyridine calcium channel blocker, which helps in reduction of blood pressure when oral therapy is not feasible. According to the company, the new formulation triples the maximum allowable infusion time per vial, known as hang time to 12 hours against the previous 4-hour hang time vial.The longer hang time which requires fewer vial changes, was achieved by adding a bacterial growth retardant.The Medicines Company senior vice president and chief customer officer Brent Furse said Cleviprex which needs fewer vial changes would help in the reduction of medication waste and provide an efficient, economical solution.